The CTC offices are currently closed for refurbishment. Access to trial TMFs and patient records will be limited during this period. We will still be able to receive post during this time, but there may be a small delay in responding to this. Our fax lines may also be subject to disruption. Where possible, please direct all correspondence via email to trial-specific email addresses. We appreciate your patience and understanding.

Due to COVID-19 and current government guidance, UCL CTC staff continue to work remotely with limited access to the office. Please continue to email the trial specific mailbox with any urgent queries. For paper CRF trials, please continue to copy and scan CRFs to the trial inboxes (remove all patient identifiers except Trial Number and Initials) until further notice.

Trial Details
Trial status:
Recruitment start date:
CRUK & AstraZeneca
Chief Investigator:
Professor Daniel Hochhauser
Recruitment target:
EudraCT number:
Contact details:
Lay summary:
AZD8931, an EGFR inhibitor, in combination with FOLFIRI: A Phase I/II study to determine the importance of schedule and activity in colorectal cancer
Design: PANTHER is a phase I/II trial in patients with recurrent or metastatic colorectal cancer.  Phase I has closed to recruitment.  The phase II part of the study is a single arm trial of AZD8931 + FOLFIRI. 
Treatment: Patients will receive AZD8931 (an EGFR/ERBB inhibitor) in combination with FOLinic acid, Fluorouracil and IRInotecan (FOLFIRI).  Patients may remain on treatment until disease progression or until a reason other than progressive disease warrants the discontinuation of all trial treatment.  
Key inclusion/exclusion criteria: Patients must have Histopathological/cytological diagnosis of non-resectable, recurrent or metastatic colorectal cancer.  Tumour must be wild type RAS, and they must have measureable disease by RECIST criteria v1.1.  Life expectancy of patients must be >3 months.  Patients may not have had chemotherapy for metastatic disease or prior treatment with agents targeting the ERBB pathway, or had previous treatment with anthracyclines or mitoxantrone. 
Duration of recruitment: Recruitment is now closed.
The primary objective for phase II is to evaluate the efficacy of AZD8931 plus FOLFIRI in terms of best overall response rate, defined using RECIST v1.1 criteria.
Trial protocols
Trial protocols must not be applied to patients treated outside trials. UCL CTC can only ensure that approved trial investigators are provided with amendments to protocols.
No protocols have been currently made available for download
Trial documents
No documents have been currently made available for download
Contact Us
Cancer Research UK & UCL Cancer Trials Centre
University College London
90 Tottenham Court Road

View map
+44 (0)20 7679 9898 (General CTC Enquiries)
020 7679 9899
University College London, Gower Street, London, WC1E 6BT +44 (0)20 7679 2000

Copyright © 2021 UCL | Disclaimer | Freedom of Information | Accessibility | Privacy | Cookies | Contact Us